Inhibitors of sclerostin: Emerging concepts

Current Opinion in Rheumatology

Volumn 26, Issue 4, 2014, Pages 447-450

  Drake, Matthew T ^a   Farr, Joshua N ^a  

^a MAYO CLINIC   (United States)

Author keywords

anabolic therapy; bone formation; monoclonal antibody; osteoporosis; sclerostin

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BLOSOZUMAB; CALCIUM; MONOCLONAL ANTIBODY; PARATHYROID HORMONE[1-34]; ROMOSOZUMAB; SCLEROSTIN; VITAMIN D; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

BIOSYNTHESIS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FINITE ELEMENT ANALYSIS; FRACTURE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; WNT SIGNALING PATHWAY; BONE DEVELOPMENT; DRUG EFFECTS; FRACTURE HEALING; GENETIC MARKER; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; BONE MORPHOGENETIC PROTEINS; FRACTURE HEALING; GENETIC MARKERS; HUMANS; OSTEOGENESIS;

EID: 84901848448     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000073     Document Type: Review

References (22)

1. Williams BO. Insights into the mechanisms of sclerostin action in regulating bone mass accrual. J Bone Miner Res 2014; 29:24-28.
2. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010; 25:2647-2656.
3. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res 2011; 26:1012-1021.
4. Hamann C, Rauner M, Hohna Y, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 2013; 28:627-638.
5. Spatz JM, Ellman R, Cloutier AM. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res 2013; 28:865-874.
6. Virk MS, Alaee F, Tang H, et al. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am 2013; 95:694-701.
7. Agholme F, Macias B, Hamang M, et al. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. J Orthop Res 2014; 32:471-476.
8. Ominsky MS, Vlasseros F, Jolette J, et al. Two does of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25:948-959.
9. Ross RD, Edwards LH, Acerbo AS, et al. Bone matrix quality following sclerostin antibody treatment. J Bone Miner Res 2013. doi: 10.1002/jbmr.2188. [Epub ahead of print]. Edited by.
10. Ominsky MS, Niu QT, Li C, et al. Tissue level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res 2013. doi.1002/jbmr.2152. [Epub ahead of print]
11. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24:578-588.
12. Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009; 24:1662-1671.
13. Tian X, Jee WS, Li X, et al. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011; 48:197-201.
14. Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 2011; 63:2385-2395.
15. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26:19-26.
16. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370:412-420.
17. Genant HK, Boonen S, Bolognese MA, et al. Effect of romosozumab on lumbar spine and hip volumetric bone mineral density (vBMD) as assessed by quantitative computed tomography (QCT). ASBMR 10/6/2013.
18. McColm J, Hu L, Womack T, et al. Single-and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014; 29:935-943.
19. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous anti-resorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008; 93:852-860. (Pubitemid 351398563)
20. Keaveny T, Myers S, Chiang A, et al. Effects of blosozumab on estimated spine and hipstrengthinpostmenopausal womenwith lowbone mineraldensity:finite element analysis of a phase-II dosing study. ASBMR 10/5/2014.
21. Becker CB. Sclerostin inhibition for osteoporosis: a new approach. N Engl J Med 2014; 370:476-477.
22. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33:747-783.